https://www.live-feeds.com/feed/why-the-latest-heart-drug-failures-should-make-us-all-more-skeptical-of-ai-hypeContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/why-the-latest-heart-drug-failures-should-make-us-all-more-skeptical-of-ai-hypehttps://www.live-feeds.com/feed/why-the-latest-heart-drug-failures-should-make-us-all-more-skeptical-of-ai-hype#u198301Fri, 13 Nov 2026 06:40:16 +0000Novartis' pelacarsen trial showed zero benefit for lowering Lp(a) cholesterol, stunning cardiologists who had high hopes for the inherited heart-risk treatment. Simultaneously, a promising cholesterol drug from Novo Nordisk failed to prevent heart attacks or strokes in a major trial. These back-to-back flops have left experts guessing about the biological pathways targeted and cast a shadow over similar programs at Amgen and Eli Lilly. The STAT analysis argues these failures should temper enthusiasm for AI hype in drug development, as computational predictions did not translate into clini